Furthermore, these results were consistent with previous studies and provided more shreds of evidence in the potential ability of RIPK3 to serve as a novel target in melanoma, especially in enhancing “hot” tumor phenotype and improving the efficacy of existing immunotherapies. This evidence concerns the gene RIPK3 and melanoma.